Idofnib 150 Soft Gelatin Capsule contains Nintedanib 150 mg, a potent intracellular inhibitor of tyrosine kinases involved in the pathogenesis of various fibrotic and neoplastic diseases. Nintedanib selectively targets receptors such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting pathways critical for angiogenesis, fibroblast proliferation, and tumor growth. Idofnib 150 is primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF), where it slows disease progression by reducing lung function decline. Additionally, it is approved for use in certain types of non-small cell lung cancer (NSCLC) in combination with chemotherapy, as well as for systemic sclerosis-associated interstitial lung disease (SSc-ILD). The soft gelatin capsule formulation facilitates oral administration and enhances patient compliance. Dosage should be individualized based on clinical response and tolerability, with monitoring for adverse effects such as gastrointestinal disturbances, hepatic enzyme elevations, and potential bleeding risks. Regular liver function tests and clinical assessments are recommended during therapy. Idofnib 150 should be used under strict medical supervision, considering contraindications and potential drug interactions. Its mechanism of action and clinical efficacy make it a valuable option in managing progressive fibrotic lung diseases and selected malignancies.